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Introduction 
Modulation of transcription in response to 
hormonal signals is mediated in part by a large 
family of structurally related receptor proteins, the 
erbA superfamily. This superfamily includes the 
receptors for steroid and thyroid hormones, vita- 
min D and retinoic acid, as well as a rapidly 
enlarging array of so-called ‘orphan’ receptors that 
lack identifiable ligands (for reviews, see Evans, 
1988; Beato, 1989). The homology amongst erbA 
superfamily members is particularly evident upon 
examining the modular structure of these proteins 
(Fig. 1). Briefly, they consist of an amino terminal 
segment of variable length and sequence, a more 
or less centrally located DNA binding domain 
featuring two zinc finger motifs, and a carboxy- 
terminal hormone binding domain. Other func- 
tions such as transcriptional activation and nuclear 
localization have been delimited to various subdo- 
mains in different receptors (Giguere et al., 1986; 
Fawell et al., 1990). The cis-acting response ele- 
ments to which erbA proteins bind typically con- 
tain two inverted or directly repeated ‘half sites’ 
(Brent et al., 1989; Nordeen et al., 1990). Current 
evidence suggests these receptors generally bind to 
response elements as dimers. However, there is an 
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emerging awareness of the existence of interac- 
tions between erbA superfamily members and rel- 
atively poorly characterized nuclear proteins. 
These interactions, which are the topic of this 
review, appear to play a role in receptor-DNA 
binding, and perhaps in transcriptional activation. 
Due to space limitations, this review will not ad- 
dress interactions of erbA superfamily proteins 
with other known erbA superfamily members 
(Glass et al., 1989), with other well-characterized 
transcription factors such as fos and jun (Jonat et 
al., 1990; Lucibello et al., 1990; Yang-Yen et al., 




Fig. 1. Domain structure of erbA superfamily proteins. Thyroid 
hormone receptor cd is shown on top, with the central 66 
amino acid DNA binding domain and the C-terminal ligand 
binding domain noted. The non-hormone binding splice variant 
erbAa2 is identical to TRal through the first 370 amino acids, 
but then the proteins diverge completely. The pl thyroid 
hormone receptor is 85-908 identical to TRal in DNA and 
ligand binding domains. but unrelated in amino terminal se- 
quence. In general, other members of the erbA superfamily 
share similarities in their DNA binding domains (45-90% 
identity), but there is little conservation amongst ligand bind- 
ing domains and no conservation amongst ammo terminal 
regions. 
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Nuclear proteins enhance binding of erbA super- 
family members to DNA 
Nuclear extracts have been shown to enhance 
or stabilize DNA binding by several erbA super- 
family members, including the receptors for gluco- 
corticoids (Cavanaugh and Simons, 1990), pro- 
gesterone (Edwards et al., 1989), estrogens 
(Feavers et al., 1987), vitamin D (Liao et al., 
1990), retinoic acid (Glass et al., 1990), and thyroid 
hormone (Murray and Towle, 1989), as well as the 
orphan receptor COUP-TF (Tsai et al., 1987). The 
most recent information comes from experiments 
involving thyroid hormone, retinoic acid and 
vitamil~ D receptors, which are believed to com- 
prise a subfamily based primarily upon sequence 
homology within their DNA binding domains. 
Murray and Towle (1989) found, using an elec- 
trophoretic mobility shift assay (EMSA), that in 
vitro translated thyroid hormone receptors (TRs) 
were unable to bind to a T3 response element 
(TRE). However, cellular extracts containing TRs 
did bind to this TRE. An extract from rat liver 
nuclei was able to restore the ability of the in vitro 
translated receptor to bind the TRE, leading to 
the formation of two gel-shifted complexes con- 
taining TR, non-TR nuclear protein, and DNA. It 
appeared that at least two non-TR proteins were 
responsible for this activity, one of which was 
detected in all tissues tested, while the other was 
detected primarily in liver. Thyroid hormone was 
found not to influence the formation of these 
complexes. For all parameters mentioned, the 1*1 
form of the TR behaved similarly to the bl form. 
These findings were confirmed and extended by 
other groups. By the use of EMSA and the more 
quantitative ABCD assay, nuclear protein(s) with 
the ability to enhance the binding of TRs to TREs 
have been discovered in many tissues and cell 
lines (Burnside et al., 1990; Lazar and Berrodin, 
1990; O’Donnell et al., 1991). A variety of TRE 
sequences have been tested, and all support this 
activity to some degree, although some are more 
potent than others. Irrelevant DNA sequences do 
not support either basal TR binding or nuclear 
protein-induced enhancement of DNA binding. 
The factor(s) necessary for the enhancement of 
TR-DNA binding has been designated T3 Recep- 
tor Auxiliary Protein. or TRAP (Darling et al., 
1991; O’Donnell et al., 1991). By gel filtration, 
TRAP activity in GE-13 cells was associated with a 
broad molecular weight range centered at - 65 
kDa (Burnside et al., 1990). In accord with this, a 
protein of approximately 63 kDa from JEG3 cells 
has been crosslinked to the TRs (O’Donnell et al., 
1991). 
To date, TRAP activity has not been associated 
with any known proteins. TR/3 itself, for example, 
does not replace TRAP activity when added exog- 
enously to the ABCD assay in place of nuclear 
extract (O’Donnell et al., 1991). Similarly, RARP, 
which is known to heterodimerize with TR (Glass 
et al., 1989), does not replace TRAP activity. 
Other proteins which have proven not to have 
TRAP activity are BSA, ovalbumin, histones, and 
high mobility group protein-l. The last is a known 
enhancer of DNA binding of other transcription 
factors (Watt and Molloy, 1988). Heat shock of 
cultured cells does not increase the amount of 
TRAP activity within those cells (E.D.R. and 
R.J.K., unpublished), arguing against a role for 
heat shock proteins in TRAP activity. 
The vitamin D receptor also requires nuclear 
extract from any of several cell types to allow 
binding of in vitro translated receptor to a vitamin 
D response element (Liao et al., 1990). Yeast 
extracts cannot mimic the activity of these mam- 
malian cell nuclear extracts (Sone et al., 1990). 
In addition, retinoic acid receptors (RARs) re- 
spond to TRAP or a TRAP-like activity. RARs 
have been shown to exhibit dependence on nuclear 
extracts for binding to TRE/RARE sequences as 
well as RARE sequences from the RARP gene 
(Glass et al., 1990). Although all vertebrate cells 
tested were positive for this activity, different 
sources of extract led to a shift in binding prefer- 
ence of RAR for various response elements. Thus, 
in the presence of extract from HL60 cells. RAR 
bound tighter to a palindromic TRE/RARE than 
to the RAR/3 gene RARE. This preference was 
reversed in the presence of HeLa extracts. Cross- 
linking studies have revealed that RARtv was 
physically associated with proteins which varied in 
size and number depending upon their source. For 
example, HeLa extracts yielded crosslinked prod- 
ucts of 55 and 65 kDa (after subtraction of the 
mass of the RAR), while HL60 cells exhibited a 
single major product of - 45 kDa. This suggests 
that a family of TRAP-like proteins exists. Cell 
specific expression of these TRAP-like proteins 
might determine which genes are actually RAR 
responsive in those cells. 
What parts of the receptor molecule are important 
for TRAP interaction? 
The only receptors for which published data 
exist to help answer this question are the TRs and 
RARs. Sequences at the N-terminus appear not to 
be important for mediating the effect of TRAP on 
TR (Hudson et al., 1990; Darling et al., 1991). 
Similarly, Glass et al. (1990) noted that a trun- 
cated RARL~ that had lost its 187 amino terminal 
residues, including the entire DNA binding do- 
main, was still able to be crosslinked to the 55 and 
65 kDa proteins from HeLa cell extracts. 
Sequences at the carboxy terminus of the mole- 
cule. on the other hand, do appear to be important 
for TRAP action to occur. Truncations of TR/3 at 
amino acid 230 (E.D.R. and R.J.K., unpublished) 
and TRa! at amino acid 210 (Lazar and Berrodin, 
1990) which remove the majority of the ligand 
binding domains while leaving the DNA binding 
domains intact, ablate the ability of TRAP to 
complex with TR and DNA as assessed by EMSA. 
In contrast with these results, Darling et al. (1991) 
have shown using the ABCD assay that similar 
mutations reduce basal binding of receptor to 
DNA, but have little effect on the response to 
TRAP. They have localized a domain immediately 
adjacent to the second zinc finger in TRa (aa 
122-149) which is critical for the enhancement of 
DNA binding due to TRAP. The reason for the 
discrepancy is not known, but may relate to the 
increased sensitivity of the ABCD assay or differ- 
ing sources of nuclear extracts. From a variety of 
deletion mutants, the region of interaction of 
RARa! was delimited to a relatively broad area 
encompassing amino acids 187-404 (Glass et al., 
1990). 
O’Donnell and Koenig (1990) investigated the 
function of a 20 amino acid segment within the 
ligand binding domain of TRP (amino acids 286 
305) that is well conserved among all members of 
the receptor superfamily (Fig. 2). Point mutations 
of this segment were found to impair the ability of 
TR@ to transactivate in transfected JEG3 cells. 




















Fig. 2. Conservation of a 20 amino acid sequence in the l&and 
binding domains of erbA superfamily members. The sequence 
of rat TRj31 aa 286-305 is shown, along with homologous 
regions of the VDR, RARP, ER, GR, reverse erbA, per- 
oxisome proliferator activated receptor, COUP-TF. and f-l- 
ZRIIBP. Residues that are identical to TR@l are in bold; 
residues that are identical or conserved are within the shaded 
area. 
Further studies revealed no defects in ligand bind- 
ing, nuclear translocation, or basal DNA binding 
to account for the inability to transactivate. Subse- 
quently, these 20 amino acids were found to be 
essential for TRAP interaction to occur (Darling 
et al., 1991; O’Donnell et al., 1991: E.D.R. and 
R.J.K., unpublished). In both EMSA and ABCD 
assays, deletion of the entire 20 ammo acid stretch 
(420) was found to abolish enhancement of DNA 
binding when cell extract was added, and point 
mutations dramatically reduced the ability of 
TRAP to enhance DNA binding. Wild-type TR 
could be crosslinked to a 63 kDa protein which 
presumably is TRAP. This crosslinking was not 
observed with the A20 mutant. Thus, the follow- 
ing three attributes of TRs appear to correlate 
with each other: the ability to transactivate target 
genes, the ability to physically interact with TRAP, 
and the ability to respond to this TRAP interac- 
tion with increased binding to TREs. The broad 
region necessary for RARa to interact with 
TRAP-like proteins includes this 20 amino acid 
domain. 
Interpretation of these results, however, is com- 
plicated by other data. The c-erbA-cY gene encodes 
at least one other product besides TRlvl, an alter- 
natively spliced form called erbA.2. ErbAa2 di- 
verges from TRcvl in its C-terminal domain (Fig. 
1) and thus does not bind T3 (Lazar et al., 1988). 
Although TRal and erbAa2 are identical in all 
domains that have been shown to interact with 
TRAP, TRAP does not enhance erbAa2-TRE 
binding (Darling et al., 1991; O’Donnell et al., 
1991). Darling et al. (1991) truncated TRa: at 
amino acid 378. providing a close approximation 
of an a-generic protein. This construct was fully 
able to interact with TRAP, indicating that the 
erbAa2 specific domain is likely to disrupt this 
interaction. The viral oncogene product v-erbA 
also is unable to respond to TRAP (O’Donnell et 
al., 1991). despite the fact that it is highly homolo- 
gous to TR& and does not contain a long cu2-like 
C-terminal extension. It is interesting to note that 
v-erbA closely resembles erbAcu2 in function: 
neither protein binds T3, and both proteins are 
constitutive repressors of T3 responsive genes 
(Koenig et al., 1989; Sap et al.. 1989). It is tempting 
to speculate that the failure to interact with TRAP 
may play a role in the inability of these proteins to 
transactivate target genes (see below). 
How might TRAP increase the affinity of nuclear 
hormone receptors for their cognate response ele- 
ments? 
fJ) A eatu@tic mechun~s~z. Although nuclear 
proteins such as TRAP may act enzymatically on 
TR (e.g. to enhance phosphorylation) and thus to 
enhance binding to the TRE, several lines of evi- 
dence argue against such a role. Burnside et al. 
(1990) found no change in the electrophoretic 
mobility of TR after the addition of extract. These 
authors also subjected their nuclear extracts to 
dialysis prior to use in DNA binding assays; this 
would presumably remove ATP. thus making 
phosphorylation a less likely candidate. We have 
found that performing binding studies at 4°C 
does not alter the ability of TRAP to enhance 
TR-TRE binding, further arguing against an en- 
zymatic process. Finally, the crosslinking studies 
with TR and RAR argue strongly for a stoichio- 
metric association between TRAP-like proteins 
and the receptors they act upon. 
(2) A direct DNA response element binding 
me~hun;.~m. TRAP and TRAP-like proteins may 
stabilize the DNA binding of receptors by directly 
binding response element sequences themselves, 
thus forming receptor-TRAP heterodimers. Hud- 
son et al. (1990) demonstrated that a HeLa cell 
extract enhanced the binding of TR and RAR to 
the EGF receptor promoter, This same DNA frag- 
ment. however, was unable to bind the nuclear 
factor in the absence of added receptor. Some of 
these same authors were later able, however, to 
modify this experiment with very different results 
(Glass et al., 1990). In this case, the RAR DNA 
binding enhancement activity was purified - 40- 
fold after high salt elution from a column made by 
coupling a concatamerized TRE to Sepharose. 
Using a similar protocol with a different TRE (the 
TSHa: promoter TRE), Darling et al. (1991) were 
able to demonstrate binding of TRAP to DNA. 
This same group was able to delineate a se- 
quence motif within the TRE-contai~ling oligo- 
nucleotide that was necessary for TRAP action to 
occur (Beebe et al., 1991). The authors found that 
the sequence (T/A)GGGA was the critical cis- 
acting determinant of TRAP activity. This se- 
quence represents one of the half-sites from the 
rate growth hormone promoter TRE. The authors 
point out that previous footprinting studies of TR 
binding to this TRE (Glass et al., 1987; Koenig et 
al., 1987) were performed in the presence of con- 
taminating nuclear proteins that might have in- 
cluded TRAP, raising the possibility that some 
components of these footprints are actually due to 
TRAP binding rather than TR. These authors also 
found that the (T/A)GGGA motif was not suffi- 
cient to allow TRAP binding; an additional half- 
site for TR binding was required. These data 
support the notion of TR-TRAP heterodimeriza- 
tion on the response element. 
(3) A ph~sicu~ ussoc~ation o~protei~s with reeep- 
tor dimers. In this model, a receptor dimer would 
sit on the response element and interact with one 
or more TRAP molecules; TRAP itself would not 
bind the response element. While no data exist to 
support such a model for TRAP, this type of 
interaction appears to occur between COUP-TF 
and the nuclear protein S300-II (Tsai et al., 1987). 
What role does the TRAP-receptor interaction 
play in receptor physiology? 
Ultimately, this is the most important question 
one can pose regarding the interactions described 
above. The TRAP-receptor interaction may sim- 
ply stabilize receptor binding to low affinity re- 
sponse elements in vivo. This could occur by alter- 
ing receptor conformation and thereby directly 
enhancing its affinity for DNA, or by TRAP itself 
binding to DNA with very high affinity and then 
dimerizing with the receptor. 
A more ambitious view is that TRAP-like pro- 
teins may be important for the ability of the 
receptor to interact with the transcription appara- 
tus. It is commonly held that receptors influence 
transcription by interacting directly or indirectly 
with components of the basal transcription ma- 
chinery. These interactions appear to stabilize the 
preinitiation complex (Klein-H&pass et al., 1990). 
To accomplish this, a protein(s) is likely to form a 
bridge between the receptor and the transcription 
apparatus; parsimony would argue TRAP may 
play such a role, because otherwise yet another 
protein would have to interact with the receptor. 
One issue relevant to this is that TRAP-receptor 
interactions are not influenced by the presence of 
ligand (Darling et al., 1991; O’Donnell et al., 
1991). How then could TRAP transmit a ligand 
dependent signal from the receptor to the tran- 
scription machinery? Here we might take ad- 
vantage of the fact that the TRAP binding site of 
the 7-R includes part of the ligand binding do- 
main. Ligand binding would then induce a confor- 
mational change in this region of the receptor, 
which would in turn cause a conformational 
change in TRAP. This ligand-dependent confor- 
mational change in TRAP may then be required 
for optimal interaction with the transcription ma- 
chinery (Fig. 3). 
It is interesting that TRAP does not enhance 
DNA 
Fig. 3. A model for TRAP activation of transcription. In the 
absence of hormone (left) TRAP and TR form a heterodimer 
on the TRE, but do not interact with the transcription machin- 
ery, and the transc~ption rate is low. In the presence of ligand 
(right), a conformational change in TR induces a change in 
TRAP, allowing the latter to interact with the transcription 
machinery and stimulate RNA synthesis. This is but one of 
numerous potential models for TRAP-receptor interactions. 
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binding of TRs to every DNA sequence capable of 
basal TR binding. Thus, while TR exhibits basal 
binding to the vitellogenin estrogen response ele- 
ment (ERE), TRAP is unable to enhance that 
binding (Darling et al., 1991). TR has previously 
been shown to be transcriptionally inactive when 
cotransfected with a reporter gene driven by this 
ERE (Glass et al., 1988). Thus, TRAP appears to 
enhance binding of TR to functionally active 
TREs, but not to other DNA sequences that bind 
TR in vitro. Perhaps when the TR binds to ERE it 
does not achieve a conformation favorable for 
interaction with TRAP. If TRAP helps form the 
bridge between the TR and the transcription ma- 
chinery, this would explain why this ERE is not a 
functional TRE. Finally, it is also possible that 
TRAP plays a role not only in hormone depen- 
dent transcriptional activation, but in hormone 
dependent repression as well, since TRAP also 
enhances TR binding to negative acting TREs in 
vitro (Burnside et al., 1990). 
This review has emphasized the roles played by 
TRAP and TRAP-like proteins in receptor-DNA 
binding and transcriptional activation. Regulated 
expression of these auxiliary proteins can be ex- 
pected to add flexibility to the transcriptional 
response. Further studies in this area should help 
unravel the complex mechanisms whereby hor- 
mones regulate specific genes, and may lead to 
new therapeutic modalities for diverse conditions 
ranging from hormone resistance to hormone re- 
sponsive malignancies. 
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